Aerostasis in Pulmonary SurgeryTechnology #ua13-116
Questions about this technology? Ask a Technology Manager
Introduction: Serosal tissue damaged during surgery needs to heal, but patients are often at risk of infection during recovery. This can lead to higher morbidity rates, longer hospital stays, or death. Likewise, lung tissue is at risk of leaking after surgery, which causes the same problems. Doctors currently use human fibrin gel to address these issues, but its effectiveness is somewhat limited in practice
Invention: This invention is a device and method for dispensing fibrin foam onto serosal tissue or lungs after surgery. It consists of three catheters that dispense fibrinogen, thrombin, and pressurized sterile air. The fibrinogen and thrombin are rapidly warmed from 0°C to 37°C, then mixed to form fibrin gel. The fibrin is then mixed with pressurized sterile air to form fibrin foam, and the mixture is sprayed onto the organ tissue or lung surface where there is damage or potential of leakage. The entire device is controlled electronically; sensors measure temperature and pressure, piezoelectric actuators control the pumping pistons, and users interact using a wireless interface.
Applications: This is intended to be used to mitigate leakage in the lungs after pulmonary surgery. It can also be used on serosal tissue damaged during surgery.
· Fibrin foam seals better than current gel/liquid products. Tests have shown a significant decrease in post-operation leakage rate after lung tissue surgery compared to current products. This device uses methods that create fibrin foam.
· Electronic control is more efficient and accurate than manual control. Current products are injected manually and require a pressure regulator to maintain an acceptable level during pumping. This invention uses electronic components to control and regulate temperate, pressure, and dispersion to within a very specific tolerance. Additionally, it utilizes wireless technology to broadcast information to a potential display, where users can easily monitor and control application of the fibrin foam.
Status: Partially demonstrated
Lead Investigator: Farid Gharagozloo, M.D., FACS
UA ID: UA13-116